SRS135 - Assessing the impact of advancements in human epidermal growth factor receptor-2-positive breast cancer therapeutics on quality of life: a systematic review and meta-analysis of randomised controlled trials

View at publisher Summarise with VIRAT
Authors: Luis Bouz Mkabaah, Eoin Patrick Kerin, Thomas Butler, Matthew Davey, Michael Joseph Kerin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Targeted molecular therapy has transformed the management of human epidermal growth factor receptor-2 (HER2+) breast cancer. Alongside survival outcomes, randomised controlled trials (RCTs) are increasingly incorporating quality of life (QoL) and patient-reported outcome measures (PROMs). Aim To systematically evaluate how RCTs of targeted therapies in breast cancer have assessed PROMs and QoL, and to investigate whether treatment effects on overall survival (OS) and progression-free survival (PFS) align with preservation of QoL. Methods A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Statistical analyses were performed using R. Results Twenty-five RCTs involving 24 234 HER2+ breast cancer patients (mean age 55.6 years, range 20–91) were included. CONSORT-PRO scores ranged from 5–9 (median 8.0). Meta-analysis demonstrated that antibody-drug conjugates (ADCs) significantly prolonged time to deterioration compared with non-ADC therapies in the metastatic setting (HR 0.64, 95% c.i. 0.49–0.83; P < 0.0001) and were associated with an improvement in QoL change from baseline (MD = 2.0 points, 95% c.i. 0.4–3.6; P = 0.015). Dual HER2 blockade significantly prolonged time to deterioration (TTD) (HR 0.81, 95% c.i. 0.69–0.94; P = 0.006). Trial-level associations between TTD and OS (P = 0.73) and between TTD and PFS (P = 0.91) were not significant. Conclusions Breast cancer RCTs increasingly integrate PROMs, reflecting a shift towards patient-centred evaluation. While treatments significantly prolonged TTD, there was no consistent evidence that survival gains translated into better QoL preservation. These findings highlight the need for future trials to balance efficacy with sustained quality of life.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Health Systems Economic Evaluations Quality of Life Cancer survivorship and care

Publication details

Journal / source
British journal of surgery
Volume
113
Issue
Supplement_2
Publication date
1 March 2026
Language
EN